Company intelligence / Profile preview
Shenyang Sansheng Pharmaceutical Co., Ltd.
- Ownership
- Private
- Employees
- ~5412
- Development stage
- Preclinical
Overview
The company has multiple approved products in China and internationally, including Recombinant Human Thrombopoietin (rhTPO) approved in China in 2005 for chemotherapy-induced thrombocytopenia and in 2010 for immune thrombocytopenia. Their etanercept product has shown strong sales growth with approval for 3 indications and a new pre-filled water injection type approved in March 2023.
- Therapeutic areas
- OncologyImmunologyHematologyDermatologyRheumatologyOphthalmologyNephrologyInfectious Diseases
- Modalities
- Monoclonal antibodiesBispecific antibodiesSmall moleculesBiological productsBiosimilarsColony-stimulating factorsTraditional Chinese Medicine
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Shenyang Sansheng Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenyang Sansheng Pharmaceutical Co., Ltd..